Hikma Pharmaceuticals PLC
LSE:HIK

Watchlist Manager
Hikma Pharmaceuticals PLC Logo
Hikma Pharmaceuticals PLC
LSE:HIK
Watchlist
Price: 2 128 GBX 1.14% Market Closed
Market Cap: 4.7B GBX
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+19%
Revenue
Forecast
+6%
Operating Income
Forecast
+12%
Net Income
Forecast
+20%

Wall Street
Price Targets

HIK Price Targets Summary
Hikma Pharmaceuticals PLC

Wall Street analysts forecast HIK stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HIK is 2 525.01 GBX with a low forecast of 2 020 GBX and a high forecast of 3 255 GBX.

HIK Lowest Forecast
Wall Street Target
2 020 GBX
5% Downside
HIK Average Forecast
Wall Street Target
2 525.01 GBX
19% Upside
HIK Highest Forecast
Wall Street Target
3 255 GBX
53% Upside
Lowest
Price Target
2 020 GBX
5% Downside
Average
Price Target
2 525.01 GBX
19% Upside
Highest
Price Target
3 255 GBX
53% Upside
Hikma Pharmaceuticals PLC Competitors:
Price Targets
S
SDZ
Sandoz Group AG
0% Upside
STAR
Strides Pharma Science Ltd
87% Upside
000538
Yunnan Baiyao Group Co Ltd
24% Upside
C
CONCORDBIO
Concord Biotech Ltd
1% Downside
S
SDZ
Sandoz Group AG
0% Upside
STAR
Strides Pharma Science Ltd
87% Upside
000538
Yunnan Baiyao Group Co Ltd
24% Upside
C
CONCORDBIO
Concord Biotech Ltd
1% Downside
IPN
Ipsen SA
22% Upside

Revenue
Forecast

Revenue Estimate
Hikma Pharmaceuticals PLC

For the last 8 years the compound annual growth rate for Hikma Pharmaceuticals PLC's revenue is 6%. The projected CAGR for the next 3 years is 6%.

6%
Past Growth
6%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Hikma Pharmaceuticals PLC

For the last 8 years the compound annual growth rate for Hikma Pharmaceuticals PLC's operating income is 5%. The projected CAGR for the next 3 years is 12%.

5%
Past Growth
12%
Estimated Growth
Estimates Accuracy
-10%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Hikma Pharmaceuticals PLC

For the last 8 years the compound annual growth rate for Hikma Pharmaceuticals PLC's net income is 11%. The projected CAGR for the next 3 years is 20%.

11%
Past Growth
20%
Estimated Growth
Estimates Accuracy
-18%
Average Miss
What are analyst estimates?

See Also

Summary
HIK intrinsic value, competitors valuation, and company profile.
DCF Valuation
HIK stock valuation using Discount Cash Flow valuation method.
Relative Valuation
HIK stock valuation using valuation multiples.
Wall Street Estimates
HIK price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
HIK stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is HIK's stock price target?
Price Target
2 525.01 GBX

According to Wall Street analysts, the average 1-year price target for HIK is 2 525.01 GBX with a low forecast of 2 020 GBX and a high forecast of 3 255 GBX.

What is Hikma Pharmaceuticals PLC's Revenue forecast?
Projected CAGR
6%

For the last 8 years the compound annual growth rate for Hikma Pharmaceuticals PLC's revenue is 6%. The projected CAGR for the next 3 years is 6%.

What is Hikma Pharmaceuticals PLC's Operating Income forecast?
Projected CAGR
12%

For the last 8 years the compound annual growth rate for Hikma Pharmaceuticals PLC's operating income is 5%. The projected CAGR for the next 3 years is 12%.

What is Hikma Pharmaceuticals PLC's Net Income forecast?
Projected CAGR
20%

For the last 8 years the compound annual growth rate for Hikma Pharmaceuticals PLC's net income is 11%. The projected CAGR for the next 3 years is 20%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 260,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.